Special Issue

Protease-Based Drug Discovery

Message from the Guest Editors

This issue will focus on protease inhibitors as potential drugs for a large variety of diseases. Hundreds of proteases are known. They can be divided into four main groups, based on their catalytic machinery (serine-, cysteine-, aspartic- and metalloproteases). This issue provides a glance at this exciting field of proteases as drug targets for the treatment of different diseases. It samples different types of proteases and a variety of diseases associated with protease activity. It sheds light on the difficulties confronting protease-based drug development and strategies to overcome them—and, on a positive note, it convincingly shows the therapeutic potential of development of protease inhibitors for the well-being of humanity. Based on your scientific record, we are delighted to invite you to join us and contribute to this important and timely issue.

Guest Editors

Prof. Dr. Ilana Nathan

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Prof. Dr. Amnon Albeck

Department of Chemistry, Bar-Ilan University, Ramat Gan, Israel

Deadline for manuscript submissions

closed (13 May 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/129578

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

